Fujita Gakuen and ROHTO Pharmaceutical Co., Ltd. established a joint venture and entered the real-world data business.

Fujita Gakuen and ROHTO Pharmaceutical Co., Ltd. established a joint venture and entered the real-world data business.

May 10, 2023

Rohto Pharmaceutical Co., Ltd. (Osaka City, Osaka Prefecture; President: Masashi Sugimoto) is pleased to announce the establishment of a business company in collaboration with Fujita Innovation Capital Co., Ltd., a subsidiary of Fujita Gakuen, a school corporation that manages universities and university hospitals (Toyoake City, Aichi Prefecture; Chairman: Kiyotaka Hoshinaga; hereinafter referred to as Fujita Gakuen). This new venture aims to promote the utilization of real-world data. Real-world data encompasses healthcare information obtained from routine clinical practices, including prescription data, electronic medical records, health check data, and patient registry data. Rohto Pharmaceutical and Fujita Gakuen are committed to strict security measures and the protection of personal information. We both will engage in business activities that range from platform construction and service design to data analysis and development consulting. These efforts are geared towards the future implementation of society in the fields of health, medicine, and caregiving.

Our Vision for Establishment

Rohto Pharmaceutical has embraced the Group comprehensive management vision, "Connect for Well-being," for 2030. We are actively pursuing various initiatives in the fields of health, pre-illness, and treatment to ensure that each individual can lead a vibrant and fulfilling life both physically and mentally. Real-world data has gained significant attention in the healthcare sector in recent years and has already been widely used overseas for product and service development. Leveraging Japan's medical expertise and medical big data, we can conduct analyses using artificial intelligence (AI) that enable quicker and more efficient evaluations of safety and efficacy than traditional development processes. This shift in approach has the potential to revolutionize product development.
Rohto Pharmaceutical shares Fujita Gakuen's strong commitment to providing services not only to its own organization but also to many individuals in the healthcare field. This led to the establishment of the joint venture company. Going forward, we will swiftly build the necessary platforms to meet customer needs and contribute to the supply of beneficial technologies and products for society as a whole.

Company Overview

Name FirstReal Healthdata Systems Co., Ltd.
Location 2nd Floor, Ginza East Building, 7-16-14 Ginza, Chuo-ku, Tokyo, Japan
Established April 28, 2023
Representative Yukio Yuzawa (President, Fujita Medical University)
Shareholders Fujita Innovation Capital Co., Ltd., ROHTO Pharmaceutical Co., Ltd.
Capital JPY 100 million, Capital Reserve: JPY 100 million
Business Activities
  • PHR (Personal Health Record) Utilization Business
  • Hospital-related business (efficiency of clinical trials, improvement of medical quality, community collaboration, hospital-based case studies, and hospital management improvement, contributing to the entire medical field)
  • Collaboration with other service providers (pharmaceuticals, foods, medical devices)


The impact of this development on our consolidated financial results for the fiscal year ending March 2023 is expected to be minimal. We will promptly notify stakeholders of any significant developments that require public disclosure.

About Fujita Gakuen

Representative Chairman Kiyotaka Hoshinaga
Location 1-98 Darakugakubo, Kutsukake-cho, Toyoake, Aichi
Fujita Gakuen aims to establish universities, provide education and research in medicine, healthcare, and hygiene, and cultivate talent that contributes to the advancement of academia and society, based on the Education Basic Law, School Education Law, and Private School Law.